Experience a transformative solution for advanced-stage epithelial cancers with EGFR inhibitors that precisely target and inhibit the Epidermal Growth Factor Receptor. By directly interfering with the growth signals in cancer cells, these inhibitors effectively slow down or halt tumor progression. This targeted approach enhances treatment efficacy, significantly improving patient outcomes and achieves a more focused and effective cancer therapy with our advanced EGFR inhibitors.
Our integrated approach drives effective drug discovery, helping you tackle resistance mechanisms and improve patient outcomes through targeted, data-driven strategies, allowing you to overcome drug resistance in your preclinical research. Crown Bioscience supports your efforts with a robust portfolio that includes HuPrime® models, patient-derived xenografts (PDX), and CRISPR technology for your studies. Enhance your research with our advanced biomarker analysis, multi-omics, spatial biology assays, and data science platforms.
With our innovative models for oncology, combined with our integrated services across in vitro, in vivo, ex vivo, and in silico platforms, allows for a comprehensive services support for extracellular receptor targeting, intracellular signaling, and drug resistance targeting. Utilizing patient-derived and cell line models, we reflect EGFR expression, mutations, and resistance, providing a robust framework for your cancer research.
Our integrated services span in vivo, in vitro, ex vivo, and in silico models, targeting extracellular receptors and intracellular signaling pathways. Utilize patient-derived and cell line models to examine EGFR expression, mutations, and resistance for translational pharmacology.
